antilipemic agents

Summary

Summary: Substances used to treat HYPERLIPIDEMIA.

Top Publications

  1. ncbi Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    Scott M Grundy
    Circulation 110:227-39. 2004
  2. pmc Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
    M John Chapman
    European Atherosclerosis Society, INSERM UMR S939, Pitie Salpetriere University Hospital, Paris 75651, France
    Eur Heart J 32:1345-61. 2011
  3. ncbi Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
    Peter Gaede
    Steno Diabetes Center, Copenhagen, Denmark
    N Engl J Med 348:383-93. 2003
  4. pmc Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
    Alexander Tenenbaum
    Cardiac Rehabilitation Institute, Sheba Medical Center, Tel Hashomer, Israel
    Cardiovasc Diabetol 11:125. 2012
  5. pmc Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994
    S Capewell
    University of Glasgow, Department of Public Health, 2 Lilybank Gardens, Glasgow G12 8RZ, UK
    Heart 81:380-6. 1999
  6. ncbi Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats
    Tetsuya Ohta
    Mitsubishi Tanabe Pharma Corporation, Kisarazu, Chiba 292 0818, Japan
    Toxicol Pathol 37:521-35. 2009
  7. ncbi EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries
    Kornelia Kotseva
    Department of Cardiovascular Medicine, National Heart and Lung Institute, Imperial College London, London, UK
    Eur J Cardiovasc Prev Rehabil 17:530-40. 2010
  8. ncbi Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications
    Stephanie E Chiuve
    Department of Nutrition, Harvard School of Public Health, 665 Huntington Ave, Boston, Massachusetts 02115, USA
    Circulation 114:160-7. 2006
  9. ncbi Adherence with statin therapy in elderly patients with and without acute coronary syndromes
    Cynthia A Jackevicius
    Department of Health Policy, Management, and Evaluation, Pharmacy Department and Women s Health Program, University Health Network Toronto General Hospital, 200 Elizabeth St, Toronto, Ontario, Canada M5G 2C4
    JAMA 288:462-7. 2002
  10. ncbi Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation
    M Villarroel
    Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Spain
    Diabetologia 54:1543-53. 2011

Research Grants

  1. Statins &Lymphoid Malignancy Risk in a Large Multi-Site Population-Based Cohort
    Marianne Ulcickas Yood; Fiscal Year: 2013
  2. Role of FoxO1 in Lipid Metabolism
    REBECCA ANNE HAEUSLER; Fiscal Year: 2013
  3. Xanthohumol and Metabolic Syndrome
    Jan Frederik Stevens; Fiscal Year: 2012
  4. EICOSANOID OXIDATION BY LIVER AND KIDNEY P450 ENZYMES
    Jerome Lasker; Fiscal Year: 2006
  5. DIETARY MODIFICATION & PROMOTION OF LIVER CARCINOGENESIS
    Hisashi Shinozuka; Fiscal Year: 1991
  6. Mitochondria-Peroxisome Fatty Acid Oxidation in Obesity
    RONALD CORTRIGHT; Fiscal Year: 2003
  7. CARDIOVASCULAR NUTRITION IN MEDICAL EDUCATION
    Scott Grundy; Fiscal Year: 2002
  8. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie M Ballantyne; Fiscal Year: 2010
  9. MAC 1/LFA 1/P150 95 AND PMN LEUKOCYTE FUNCTION
    Christie Ballantyne; Fiscal Year: 2002
  10. Characteristics and Costs of Impaired Fasting Glucose
    Gregory Nichols; Fiscal Year: 2005

Detail Information

Publications343 found, 100 shown here

  1. ncbi Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    Scott M Grundy
    Circulation 110:227-39. 2004
    ..Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy...
  2. pmc Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
    M John Chapman
    European Atherosclerosis Society, INSERM UMR S939, Pitie Salpetriere University Hospital, Paris 75651, France
    Eur Heart J 32:1345-61. 2011
    ..These recommendations will facilitate reduction in the substantial cardiovascular risk that persists in patients with cardiometabolic abnormalities at LDL-C goal...
  3. ncbi Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
    Peter Gaede
    Steno Diabetes Center, Copenhagen, Denmark
    N Engl J Med 348:383-93. 2003
    ....
  4. pmc Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
    Alexander Tenenbaum
    Cardiac Rehabilitation Institute, Sheba Medical Center, Tel Hashomer, Israel
    Cardiovasc Diabetol 11:125. 2012
    ..Fibrates currently constitute an indispensable part of the modern anti-dyslipidemic arsenal for patients with atherogenic dyslipidemia...
  5. pmc Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994
    S Capewell
    University of Glasgow, Department of Public Health, 2 Lilybank Gardens, Glasgow G12 8RZ, UK
    Heart 81:380-6. 1999
    ..To estimate the fall in coronary heart disease (CHD) mortality in Scotland attributable to medical and surgical treatments, and risk factor changes, between 1975 and 1994...
  6. ncbi Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats
    Tetsuya Ohta
    Mitsubishi Tanabe Pharma Corporation, Kisarazu, Chiba 292 0818, Japan
    Toxicol Pathol 37:521-35. 2009
    ..Finally, several metabolites related to liver function, kidney function, cell damage, and cell proliferation were altered by fenofibrate-induced toxicity at this dose...
  7. ncbi EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries
    Kornelia Kotseva
    Department of Cardiovascular Medicine, National Heart and Lung Institute, Imperial College London, London, UK
    Eur J Cardiovasc Prev Rehabil 17:530-40. 2010
    ..To determine whether the 2003 Joint European Societies' guidelines on cardiovascular disease prevention in people at high cardiovascular risk have been followed in general practice...
  8. ncbi Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications
    Stephanie E Chiuve
    Department of Nutrition, Harvard School of Public Health, 665 Huntington Ave, Boston, Massachusetts 02115, USA
    Circulation 114:160-7. 2006
    ..The burden of CHD that could be avoided through adherence to these modifiable lifestyle factors has not been assessed among middle-aged and older US men, specifically men taking medications for hypertension or hypercholesterolemia...
  9. ncbi Adherence with statin therapy in elderly patients with and without acute coronary syndromes
    Cynthia A Jackevicius
    Department of Health Policy, Management, and Evaluation, Pharmacy Department and Women s Health Program, University Health Network Toronto General Hospital, 200 Elizabeth St, Toronto, Ontario, Canada M5G 2C4
    JAMA 288:462-7. 2002
    ..Research prior to these trials of older lipid-lowering agents demonstrated low levels of 1-year adherence...
  10. ncbi Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation
    M Villarroel
    Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Spain
    Diabetologia 54:1543-53. 2011
    ..To shed light on this issue we have explored the effect of fenofibric acid on the barrier function of human retinal pigment epithelium (RPE) cells...
  11. ncbi Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
    T M E Davis
    School of Medicine and Pharmacology, Fremantle Hospital, University of Western Australia, Fremantle, WA, Australia
    Diabetologia 54:280-90. 2011
    ..We assessed fenofibrate's renal effects overall and in a FIELD washout sub-study...
  12. ncbi Supplementing obese Zucker rats with niacin induces the transition of glycolytic to oxidative skeletal muscle fibers
    Robert Ringseis
    Institute of Animal Nutrition and Nutrition Physiology, Justus Liebig University, Giessen, Germany
    J Nutr 143:125-31. 2013
    ..The increased utilization of fatty acids by muscle might contribute to the strong TG-lowering effect of niacin treatment...
  13. pmc Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial
    Russell Scott
    Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand
    Cardiovasc Diabetol 10:102. 2011
    ....
  14. ncbi Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
    Min Jun
    The George Institute for International Health, University of Sydney, Sydney, Australia
    Lancet 375:1875-84. 2010
    ..Several clinical trials have reported inconsistent findings for the effect of fibrates on cardiovascular risk. We undertook a systematic review and meta-analysis to investigate the effects of fibrates on major clinical outcomes...
  15. pmc Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis
    Matthias Briel
    Department of Clinical Epidemiology and Biostatistics, McMaster University, 1200 Main Street West, Hamilton, ON, Canada
    BMJ 338:b92. 2009
    ....
  16. ncbi The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
    T A Pearson
    Department of Community and Preventive Medicine, University of Rochester School of Medicine, NY 14642, USA
    Arch Intern Med 160:459-67. 2000
    ....
  17. ncbi Fenofibrate: a review of its use in dyslipidaemia
    Kate McKeage
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 71:1917-46. 2011
    ..Thus, in patients with dyslipidaemia, particularly atherogenic dyslipidaemia, fenofibrate is a useful treatment option either alone or in combination with a statin...
  18. ncbi Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
    A Keech
    Lancet 366:1849-61. 2005
    ..We designed the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study to assess the effect of fenofibrate on cardiovascular disease events in these patients...
  19. pmc Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Alexander Tenenbaum
    Cardiac Rehabilitation Institute, Sheba Medical Center, 52621 Tel Hashomer, Israel
    Cardiovasc Diabetol 11:140. 2012
    ....
  20. ncbi Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate
    C Kyrklund
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 69:340-5. 2001
    ..The risk of developing myopathy during concomitant therapy with lovastatin and a fibrate may be smaller with bezafibrate than with gemfibrozil...
  21. ncbi Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
    I Issemann
    Imperial Chemical Industries PLC, Central Toxicology Laboratory, Alderley Park, Macclesfield, UK
    Nature 347:645-50. 1990
    ..Identification of a peroxisome proliferator-activated receptor should help elucidate the mechanism of the hypolipidaemic effect of these hepatocarcinogens and aid evaluation of their potential carcinogenic risk to man...
  22. ncbi Contemporary management of dyslipidemia in high-risk patients: targets still not met
    Andrew T Yan
    Canadian Heart Research Centre and Terrence Donnelly Heart Centre, Division of Cardiology, Toronto, Ontario, Canada
    Am J Med 119:676-83. 2006
    ..Our objective was to evaluate treatment patterns and the attainment of current National Cholesterol Education Program (NCEP)-recommended lipid targets in unselected high-risk ambulatory patients...
  23. ncbi PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect
    Sorin Tunaru
    Institute of Pharmacology, University of Heidelberg, Heidelberg, Germany
    Nat Med 9:352-5. 2003
    ..The identification of the nicotinic acid receptor may be useful in the development of new drugs to treat dyslipidemia...
  24. ncbi European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by represent
    Ian Graham
    Department of Cardiology, The Adelaide and Meath Hospital, Tallaght, Dublin, Ireland
    Eur J Cardiovasc Prev Rehabil 14:S1-113. 2007
  25. ncbi Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation
    Atsuko Tomizawa
    Department of Endocrinology and Metabolism, Dokkyo University School of Medicine, Mibu, Tochigi 321 0293, Japan
    Metabolism 60:513-22. 2011
    ..Our findings suggest that fenofibrate might exert a protective effect on the microvasculature by suppressing inflammation and apoptosis through AMPK activation beyond its lipid-lowering actions...
  26. ncbi Antiatherogenic small, dense HDL--guardian angel of the arterial wall?
    Anatol Kontush
    National Institute for Health and Medical Research INSERM, Unité 551, Hopital de la Pitie, Paris, France
    Nat Clin Pract Cardiovasc Med 3:144-53. 2006
    ..Induction of selective increase in the circulating concentrations of small, dense HDL3 particles with increased antiatherogenic activity seems especially promising, particularly for therapy of atherogenic dyslipidemia...
  27. pmc Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome
    Renata Belfort
    The University of Texas Health Science Center at San Antonio, Diabetes Division, Room 3 380S, 7703 Floyd Curl Drive, San Antonio, Texas 78284 3900, USA
    J Clin Endocrinol Metab 95:829-36. 2010
    ..Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist widely used in clinical practice, but its mechanism of action is incompletely understood...
  28. ncbi Gender disparities in lipid-lowering therapy among veterans with diabetes
    Varsha G Vimalananda
    Center for Health Quality, Outcomes and Economic Research, Bedford VA Medical Center, Bedford, Massachusetts, USA
    Womens Health Issues 21:S176-81. 2011
    ..We sought to compare lipid-lowering therapy among female and male veterans with diabetes and hyperlipidemia...
  29. ncbi The vitamin E reduces liver lipoperoxidation and fibrosis in a model of nonalcoholic steatohepatitis
    Idilio Zamin Jr
    Post Graduation Program in Hepatology, Fundacao Faculdade Federal de Ciencias Medicas de Porto Alegre, Porto Alegre, RS, Brazil
    Arq Gastroenterol 47:86-92. 2010
    ..No effective treatment is available for nonalcoholic steatohepatitis in nowadays...
  30. ncbi Fenofibrate and metabolic syndrome
    Aldi T Kraja
    Division of Statistical Genomics, Washington University School of Medicine, 4444 Forest Park Ave, Campus Box 8506, St Louis, MO 63110, USA
    Endocr Metab Immune Disord Drug Targets 10:138-48. 2010
    ..However, more work is needed to specifically identify which individuals derive a benefit from FF administration in terms of clinical outcomes and which do not - particularly in the context of type 2 diabetes...
  31. ncbi Comparative effects of lipid-lowering therapies
    Michael H Davidson
    Radiant Research, Rush Medical College, Rush University Medical Center, Chicago, IL 60602, USA
    Prog Cardiovasc Dis 47:73-104. 2004
    ..This trend portends an ever-growing need for the aggressive and judicious use of different antilipidemic medication(s) in patients at risk for all forms of atherosclerotic vascular disease...
  32. ncbi Fenofibrate-induced decrease of expression of CYP2C11 and CYP2C6 in rat
    Rostislav Vecera
    Institute of Pharmacology, Faculty of Medicine and Dentistry, Palacky University, Hnevotínská, 3, 775 15 Olomouc, Czech Republic
    Biopharm Drug Dispos 32:482-7. 2011
    ..This type of drug interaction has been observed previously and the results presented here could contribute to the explanation of their mechanism...
  33. ncbi Drug treatment and cost of cardiovascular disease in Australia
    Zanfina Ademi
    Department of Epidemiology and Preventive Medicine, Centre for Cardiovascular Research and Education in Therapeutics, Monash University, Victoria 3004, Australia
    Cardiovasc Ther 27:164-72. 2009
    ..Given the evidence of the effectiveness and cost-effectiveness of treating all types of vascular diseases, the present study suggests that there is scope to improve the treatment of these high-risk participants in Australia...
  34. pmc Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants
    Josyf C Mychaleckyj
    Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA
    Diabetes Care 35:1008-14. 2012
    ..To assess the reversibility of the elevation of serum creatinine levels in patients with diabetes after 5 years of continuous on-trial fenofibrate therapy...
  35. pmc Hyperlipidemia as a risk factor for cardiovascular disease
    Robert H Nelson
    Division of Endocrinology, Department of Family Medicine, Mayo College of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Prim Care 40:195-211. 2013
    ....
  36. pmc Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial
    Gissette Reyes-Soffer
    Department of Medicine, Columbia University Medical Center, New York, NY, USA
    Diabetes Care 36:422-8. 2013
    ..We examined the effects of FENO-S on postprandial (PP) lipid and lipoprotein levels in a subgroup of ACCORD Lipid subjects...
  37. ncbi Triglycerides and risk for coronary artery disease
    Patrick McBride
    Preventive Cardiology Program, University of Wisconsin School of Medicine and Public Health, 2150 HSLC, 750 Highland Avenue, Madison, WI 53705, USA
    Curr Atheroscler Rep 10:386-90. 2008
    ..Treatment of elevated TGs in clinical trials has been shown to reduce CVD events, cardiac deaths, and total mortality...
  38. pmc Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise
    Nicholas S Downing
    Yale University School of Medicine, New Haven, Connecticut, USA
    Arch Intern Med 172:724-30. 2012
    ....
  39. pmc Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
    Kushwin Rajamani
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
    Lancet 373:1780-8. 2009
    ..Our aim was to assess the effect of fenofibrate on amputation events in a large cohort of patients with type 2 diabetes...
  40. ncbi Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway
    Jaetaek Kim
    Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Chung Ang University, 224 1 Heuk Seok dong, Dongjak Ku, Seoul 156 755, South Korea
    Exp Eye Res 84:886-93. 2007
    ..Thus fenofibrate may have a novel therapeutic property that can control unwanted cell death found in diabetic retinopathy...
  41. ncbi The role of non-HDL cholesterol in risk stratification for coronary artery disease
    Jamal S Rana
    Division of Cardiology and Oppenheimer Atherosclerosis Research Center, Cedars Sinai Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Curr Atheroscler Rep 14:130-4. 2012
    ..Future guidelines should emphasize the importance of non-HDL-C for guiding cardiovascular prevention strategies with an increased need to have non-HDL-C reported on routine lipid panels...
  42. pmc A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network
    Stella Aslibekyan
    Departments of Epidemiology, School of Public Health, University of Alabama at Birmingham, Alabama, USA
    Pharmacogenet Genomics 22:191-7. 2012
    ..This study provides the first genome-wide examination of fenofibrate effects on systemic inflammation...
  43. ncbi Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke
    Peter M Rothwell
    Stroke Prevention Research Unit, Department of Clinical Neurology, University of Oxford, Oxford, UK
    Lancet 377:1681-92. 2011
    ..We review the main medical treatments that should be considered for most patients with transient ischaemic attack or ischaemic stroke in the acute phase and the long term, and draw attention to recent developments...
  44. ncbi Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Alexander Tenenbaum
    Cardiac Rehabilitation Institute, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Adv Cardiol 45:127-53. 2008
    ....
  45. ncbi Cardiovascular risk and body-fat abnormalities in HIV-infected adults
    Steven Grinspoon
    Program in Nutritional Metabolism and the Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    N Engl J Med 352:48-62. 2005
  46. ncbi Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial
    Robyn Tamblyn
    Department of Epidemiology and Bio statistics, McGill University, Montreal, Quebec, Canada
    Med Decis Making 30:176-88. 2010
    ..Treatment side effects, cost, and complexity are common reasons for nonadherence, and physicians are often unaware of these potentially modifiable problems...
  47. ncbi Antidiabetic and antihyperlipidemic activity of ethyl acetate:isopropanol (1:1) fraction of Vernonia anthelmintica seeds in streptozotocin induced diabetic rats
    Shaik Sameena Fatima
    Department of Biochemistry, S V University, Tirupati 517502, AP, India
    Food Chem Toxicol 48:495-501. 2010
    ..anthelmintica seeds. From the present study, it is evident that, the seeds of V. anthelmintica possess significant antidiabetic and antihyperlipidemic property without evident toxic effects...
  48. ncbi The cardiovascular effects of peroxisome proliferator-activated receptor agonists
    Sayuri N Friedland
    Division of Cardiology, Jewish General Hospital McGill University, Montreal, Quebec, Canada
    Am J Med 125:126-33. 2012
    ..The critical question of why peroxisome proliferator-activated receptor agonists seem to improve cardiovascular risk factors without significantly improving cardiovascular outcomes requires further investigation...
  49. ncbi Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia
    Yasushi Saito
    Department of Clinical Cell Biology, Graduate School of Medicine, Chiba University, Chiba, Japan
    Atherosclerosis 194:505-11. 2007
    ..The current study does not suggest a dose-related effect of rosuvastatin in lowering TG in hypertriglyceridemic Japanese patients, although dose-related improvements in other elements of the atherogenic lipid profile were observed...
  50. pmc Use of fibrates in the United States and Canada
    Cynthia A Jackevicius
    Department of Pharmacy Practice and Administration, Western University of Health Sciences, College of Pharmacy, 309 E Second St, Pomona, CA 91766, USA
    JAMA 305:1217-24. 2011
    ..The evidence for clinical benefit in outcomes with the use of fibrates is heavily weighted on the use of the older fibrates such as gemfibrozil and clofibrate...
  51. ncbi Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome
    Richard W Nesto
    Department of Cardiovascular Medicine, Lahey Clinic, Burlington, Massachusetts 02493, USA
    Am J Cardiovasc Drugs 5:379-87. 2005
    ....
  52. pmc Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study
    Tamio Teramoto
    Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    Cardiovasc Diabetol 11:29. 2012
    ..We investigated glycemic control, relationship between lipid metabolism and HbA1c, and safety in diabetic patients treated with bezafibrate...
  53. pmc Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey
    P Primatesta
    Department of Epidemiology and Public Health, Royal Free and University College Medical School, London WC1E 6BT
    BMJ 321:1322-5. 2000
    ..To evaluate the prevalence of the use of lipid lowering agents and its relation to blood lipid concentrations in English adults...
  54. ncbi Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
    B G Brown
    Department of Medicine, University of Washington School of Medicine, Seattle 98195, USA
    N Engl J Med 345:1583-92. 2001
    ..CONCLUSIONS: Simvastatin plus niacin provides marked clinical and angiographically measurable benefits in patients with coronary disease and low HDL levels. The use of antioxidant vitamins in this setting must be questioned...
  55. pmc Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib
    Laurent Yvan-Charvet
    Division of Molecular Medicine, Department of Medicine, Columbia University, 630 W 168th St, New York, NY 10032, USA
    Arterioscler Thromb Vasc Biol 30:1430-8. 2010
    ....
  56. ncbi Plasma concentrations of active simvastatin acid are increased by gemfibrozil
    J T Backman
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Finland
    Clin Pharmacol Ther 68:122-9. 2000
    ..The aim of this study was to determine whether gemfibrozil affects the pharmacokinetics of simvastatin and whether it affects CYP3A4 activity in vitro...
  57. ncbi Hypoglycemic and antihyperglycemic activity of Aegle marmelos seed extract in normal and diabetic rats
    Achyut Narayan Kesari
    Alternative Therapeutics Unit, Drug Development Division, Medicinal Research Lab, Department of Chemistry, University of Allahabad, Allahabad 211002, India
    J Ethnopharmacol 107:374-9. 2006
    ..97 and 45.77% in low density lipoprotein (LDL) and triglyceride (TG), respectively. These results clearly indicate that aqueous seed extract of Aegle marmelos possess antidiabetic and hypolipidemic effects in diabetic rats...
  58. ncbi Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin
    C J Halkes
    Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
    Arterioscler Thromb Vasc Biol 21:1526-30. 2001
    ..Fasting C3 is associated with waist circumference, but postprandial C3 increment is associated with postprandial lipemia. Fasting and postprandial C3 concentrations decrease after treatment with simvastatin...
  59. ncbi Conjugated linoleic acid activates peroxisome proliferator-activated receptor alpha and beta subtypes but does not induce hepatic peroxisome proliferation in Sprague-Dawley rats
    S Y Moya-Camarena
    Department of Foods and Nutrition, Purdue University, West Lafayette, IN 47907, USA
    Biochim Biophys Acta 1436:331-42. 1999
    ..These data suggest that while CLA was able to activate PPARs it is not a peroxisome proliferator in SD rats...
  60. pmc "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study
    Alexander Tenenbaum
    Cardiac Rehabilitation Institute, Sheba Medical Center, Tel Hashomer, Israel
    Cardiovasc Diabetol 9:24. 2010
    ..In patients without dyslipidemia this favorable effect - as expected - was absent...
  61. ncbi Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study
    Justin M S Lee
    Department of Cardiovascular Medicine, University of Oxford and Oxford Centre for Clinical Magnetic Resonance Research OCMR, Oxford, United Kingdom
    J Am Coll Cardiol 54:1787-94. 2009
    ..Our aim was to determine the effects of high-dose (2 g) nicotinic acid (NA) on progression of atherosclerosis and measures of vascular function...
  62. ncbi Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study
    Chao Qiang Lai
    Nutrition and Genomics Laboratory, JM USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington St, Boston, MA 02111, USA
    Arterioscler Thromb Vasc Biol 27:1417-25. 2007
    ..Apolipoprotein A5 (APOA5) is a key determinant of plasma triglyceride (TG) concentrations. Genetic variation at the APOA5 locus could be responsible for some of the observed differences in response to fenofibrate therapy...
  63. ncbi Molecular identification of high and low affinity receptors for nicotinic acid
    Alan Wise
    Department of 7TMR Systems Research, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom
    J Biol Chem 278:9869-74. 2003
    ..The discovery of HM74A as a molecular target for nicotinic acid may facilitate the discovery of superior drug molecules to treat dyslipidemia...
  64. ncbi Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006
    Elena V Kuklina
    Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Hwy NE, Mailstop K 37, Atlanta, GA 30341 3724, USA
    JAMA 302:2104-10. 2009
    ..Studies show that a large proportion of adults with high levels of low-density lipoprotein cholesterol (LDL-C) remain untreated or undertreated despite growing use of lipid-lowering medications...
  65. ncbi Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio 44195, USA
    JAMA 297:1362-73. 2007
    ..Fibrates are weak agonists of peroxisome proliferator-activated receptor alpha (PPAR-alpha). No trials have reported effects of more potent and selective agents...
  66. ncbi Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation
    Robert Kleemann
    Gaubius Laboratory Nederlandse Organisatie voor toegepast natuurwetenschappelijk onderzoek TNO Prevention and Health, Leiden, The Netherlands
    Blood 101:545-51. 2003
    ..Our findings identify C/EBP-beta and p50-NFkappaB as novel targets for PPAR-alpha and provide a molecular explanation for the reduction of plasma CRP levels by fibrates...
  67. ncbi Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial
    James A de Lemos
    Donald W Reynolds Cardiovascular Clinical Research Center, The University of Texas Southwestern Medical Center, Dallas 75390 9047, USA
    JAMA 292:1307-16. 2004
    ..Limited data are available evaluating how the timing and intensity of statin therapy following an acute coronary syndrome (ACS) event affect clinical outcome...
  68. ncbi Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
    H B Rubins
    Center for Chronic Disease Outcomes Research, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA
    N Engl J Med 341:410-8. 1999
    ....
  69. ncbi Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
    Scott M Grundy
    J Am Coll Cardiol 44:720-32. 2004
    ..Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy...
  70. ncbi Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic Momordica charantia (karela) fruit extract in streptozotocin-induced diabetic rats
    I Ahmed
    Departments of Anatomy and Biochemistry, Faculty of Medicine and Health Sciences, UAE University, P.O. Box 17666, Al Ain, United Arab Emirates
    Diabetes Res Clin Pract 51:155-61. 2001
    ..These results suggest that M. charantia fruit extract exhibits hypolipidemic as well as hypoglycemic effects in the STZ-induced diabetic rat...
  71. ncbi Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis
    Philip J Larsen
    Rheoscience, Rødovre, Denmark
    Diabetes 52:2249-59. 2003
    ....
  72. ncbi Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet
    Caroline Fernandes-Santos
    Laboratory of Morphometry and Cardiovascular Morphology, Biomedical Center, Institute of Biology, State University of Rio de Janeiro, Rio de Janeiro, Brazil
    Pancreas 38:e80-6. 2009
    ....
  73. ncbi Effect of a multifactorial intervention on mortality in type 2 diabetes
    Peter Gaede
    Steno Diabetes Center, Copenhagen, Denmark
    N Engl J Med 358:580-91. 2008
    ..We evaluated whether this approach would have an effect on the rates of death from any cause and from cardiovascular causes...
  74. ncbi Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation
    Eun Hee Koh
    Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea
    Diabetes 52:2331-7. 2003
    ....
  75. pmc Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy
    Peter P Toth
    Department of Family and Community Medicine, University of Illinois College of Medicine, Peoria, CGH Medical Center, 101 East Miller Road, Sterling, IL 61081, USA
    Vasc Health Risk Manag 8:39-44. 2012
    ....
  76. ncbi Recent advances in niacin and lipid metabolism
    Vaijinath S Kamanna
    Atherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Long Beach, California 90822, USA
    Curr Opin Lipidol 24:239-45. 2013
    ..This review focuses on the current understanding of the physiological mechanisms of action of niacin on lipid metabolism and atherosclerosis...
  77. pmc The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus
    Peter P Toth
    CGH Medical Center, 101 East Miller Rd, Sterling, IL, 61081, USA
    Cardiovasc Diabetol 11:109. 2012
    ....
  78. ncbi Triglycerides: how much credit do they deserve?
    Payal Kohli
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Med Clin North Am 96:39-55. 2012
    ....
  79. ncbi Management of hyperlipidemia in pediatrics
    Stephen R Daniels
    Department of Pediatrics, University of Colorado School of Medicine, Children s Hospital Colorado, Aurora, Colorado, USA
    Curr Opin Cardiol 27:92-7. 2012
    ..The purpose of this review is to provide up-to-date information on diagnosis and management of hyperlipidemia in children and adolescents...
  80. ncbi Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies
    William Nseir
    Department of Internal Medicine, Holy Family Hospital, Nazareth, Israel
    Dig Dis Sci 57:1773-81. 2012
    ....
  81. ncbi Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population
    Kandace L Amend
    Epidemiology Division, OptumInsight, Ann Arbor, MI, USA
    Ann Pharmacother 45:1230-9. 2011
    ..The incidence of hospitalized rhabdomyolysis is not well characterized among patients taking statin-fibrate combination therapies...
  82. ncbi Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: results from the EARLY study
    M M Engler
    University of California, San Francisco, San Francisco, CA 94143 0610, USA
    Int J Clin Pharmacol Ther 42:672-9. 2004
    ....
  83. ncbi Activation of peroxisome proliferator-activated receptor-α (PPARα) suppresses postprandial lipidemia through fatty acid oxidation in enterocytes
    Rino Kimura
    Laboratory of Molecular Function of Food, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Uji, Kyoto 611 0011, Japan
    Biochem Biophys Res Commun 410:1-6. 2011
    ....
  84. ncbi Antihyperlipidemic effect of chlorogenic acid and tetrahydrocurcumin in rats subjected to diabetogenic agents
    K Karthikesan
    Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar 608 002, Tamilnadu, India
    Chem Biol Interact 188:643-50. 2010
    ..These results indicate that combination of THC and CGA can potentially ameliorate lipid abnormalities in experimental type 2 diabetes...
  85. ncbi Modulating effects of chlorogenic acid on lipids and glucose metabolism and expression of hepatic peroxisome proliferator-activated receptor-alpha in golden hamsters fed on high fat diet
    Shu Yuan Li
    Division of Nutrition and Biochemistry, Institute of Sports Medicine, Third Hospital, Peking University, Beijing 100191, China
    Biomed Environ Sci 22:122-9. 2009
    ..To examine the effects of chlorogenic acid (CGA) on lipid and glucose metabolism under a high dietary fat burden and to explore the possible role of peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in these effects...
  86. ncbi Lipid-lowering effect of berberine in human subjects and rats
    Yueshan Hu
    Avera Institute for Human Genetics, Sioux Falls, SD 57108, USA
    Phytomedicine 19:861-7. 2012
    ..Collectively, this study demonstrates that berberine is a potent lipid-lowering compound with a moderate weight loss effect, and may have a possible potential role in osteoporosis treatment/prevention...
  87. pmc Fenofibrate-induced nuclear translocation of FoxO3A triggers Bim-mediated apoptosis in glioblastoma cells in vitro
    Anna Wilk
    Neurological Cancer Research, Louisiana State University Health Sciences Center, New Orleans, LA, USA
    Cell Cycle 11:2660-71. 2012
    ..These properties of fenofibrate, coupled with its low systemic toxicity, make it a good candidate in support of conventional therapies against glial tumors...
  88. ncbi Millet consumption decreased serum concentration of triglyceride and C-reactive protein but not oxidative status in hyperlipidemic rats
    Sun Hee Lee
    Department of Food and Nutrition, Hanyang University, Seoul, South Korea
    Nutr Res 30:290-6. 2010
    ..In conclusion, FM and proso millet may prevent cardiovascular disease by reducing plasma triglycerides in hyperlipidemic rats; in contrast, sorghum increases total cholesterol, HDL-cholesterol, and LDL-cholesterol concentrations...
  89. ncbi Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy
    Sajoscha A Sorrentino
    Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover, Hannover, Germany
    Circulation 121:110-22. 2010
    ..Moreover, in diabetic patients, we examined the impact of extended-release (ER) niacin therapy on the endothelial effects of HDL...
  90. ncbi Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial
    A C Keech
    NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia
    Lancet 370:1687-97. 2007
    ..Our aim was to assess whether long-term lipid-lowering therapy with fenofibrate could reduce the progression of retinopathy and the need for laser treatment in patients with type 2 diabetes mellitus...
  91. doi Lipid screening and cardiovascular health in childhood
    Stephen R Daniels
    Pediatrics 122:198-208. 2008
    ....
  92. ncbi Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes
    M R Taskinen
    Department of Medicine, Division of Cardiology, Helsinki University Central Hospital, Biomedicum, Haartmaninkatu 8, Helsinki, Finland
    Diabetologia 53:1846-55. 2010
    ....
  93. ncbi Hypoglycemic and hypolipidemic effects of flavonoid rich extract from Eugenia jambolana seeds on streptozotocin induced diabetic rats
    Bhavna Sharma
    Molecular Endocrinology Laboratory, Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247 667, Uttarakhand, India
    Food Chem Toxicol 46:2376-83. 2008
    ..The present data suggests that the flavonoid rich extract from EJ plant has both hypoglycemic and hypolipidemic effects which can help the cure and management of diabetes...
  94. ncbi Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats
    H J Lee
    Department of Pharmacology, Dong A University College of Medicine, Busan, Republic of Korea
    Biochem Biophys Res Commun 296:293-9. 2002
    ..It might result in reduction of adiposity of truncal adipose tissue and skeletal muscle. We suggest that reduction of adiposity in trunk and skeletal muscle might improve insulin sensitivity...
  95. ncbi European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by r
    Ian Graham
    Department of Cardiology, The Adelaide and Meath Hospital, Tallaght, Doublin, Ireland
    Eur J Cardiovasc Prev Rehabil 14:E1-40. 2007
  96. ncbi Antidiabetic and antioxidant effects of oleanolic acid from Ligustrum lucidum Ait in alloxan-induced diabetic rats
    Dawei Gao
    Department of Biological Engineering, College of Environmental and Chemical Engineering, Yanshan University, No 438 Hebei Street, Qinhuangdao 066004, China
    Phytother Res 23:1257-62. 2009
    ..The antioxidant ability of OA might be one of the mechanisms of its hypoglycemic and hypolipidemic effects...
  97. ncbi Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel
    James Shepherd
    Department of Vascular Biochemistry, Glasgow Royal Infirmary, Glasgow, UK
    Curr Med Res Opin 21:665-82. 2005
    ..Prolonged-release nicotinic acid with improved tolerability compared with previous formulations may have obvious advantages for use in this setting...
  98. pmc Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study
    Ru Dee Ting
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia
    Diabetes Care 35:218-25. 2012
    ..We investigated fenofibrate's effects on cardiovascular and end-stage renal disease (ESRD) events, according to eGFR, in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study...
  99. ncbi Lipid-lowering drugs and risk for cancer
    Terje R Pedersen
    Center for Preventive Medicine, Oslo University Hospital, Oslo, Norway
    Curr Atheroscler Rep 11:350-7. 2009
    ..Whether statins and other lipid-lowering drugs will increase the risk of cancer when used over several decades is at present unknown...
  100. ncbi Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine
    Michael Lever
    Biochemistry Unit, Canterbury Health Laboratories, P O Box 151, Christchurch, 8140, New Zealand
    Cardiovasc Drugs Ther 23:395-401. 2009
    ..These patients are often treated with fibrates which alter renal function and raise plasma homocysteine concentrations. We suggest there is a connection between fibrate treatment and betaine excretion...

Research Grants63

  1. Statins &Lymphoid Malignancy Risk in a Large Multi-Site Population-Based Cohort
    Marianne Ulcickas Yood; Fiscal Year: 2013
    ....
  2. Role of FoxO1 in Lipid Metabolism
    REBECCA ANNE HAEUSLER; Fiscal Year: 2013
    ..These data will provide a roadmap to design new therapeutic interventions in the treatment of dyslipidemia within the rapidly growing population of people with the metabolic syndrome. ..
  3. Xanthohumol and Metabolic Syndrome
    Jan Frederik Stevens; Fiscal Year: 2012
    ....
  4. EICOSANOID OXIDATION BY LIVER AND KIDNEY P450 ENZYMES
    Jerome Lasker; Fiscal Year: 2006
    ..abstract_text> ..
  5. DIETARY MODIFICATION & PROMOTION OF LIVER CARCINOGENESIS
    Hisashi Shinozuka; Fiscal Year: 1991
    ..These studies will provide critical information regarding possible consequences of the diet-induced membrane lipid peroxidation and its mechanistic significance related to liver tumor promotion...
  6. Mitochondria-Peroxisome Fatty Acid Oxidation in Obesity
    RONALD CORTRIGHT; Fiscal Year: 2003
    ..abstract_text> ..
  7. CARDIOVASCULAR NUTRITION IN MEDICAL EDUCATION
    Scott Grundy; Fiscal Year: 2002
    ..The long term goal is to produce graduates who routinely address nutrition and exercise for cardiovascular health with their patients. ..
  8. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie M Ballantyne; Fiscal Year: 2010
    ....
  9. MAC 1/LFA 1/P150 95 AND PMN LEUKOCYTE FUNCTION
    Christie Ballantyne; Fiscal Year: 2002
    ..3. Characterize the contribution of each CD11 integrin on the host response to common bacterial and fungal pathogens in vitro and in vivo. ..
  10. Characteristics and Costs of Impaired Fasting Glucose
    Gregory Nichols; Fiscal Year: 2005
    ..Finally, we will calculate and compare the costs of medical care for patients in each FPG stage, and estimate multivariate models to identify factors that contribute to medical costs in each stage. ..
  11. Biomarkers and Outcomes in the Diabetes Prevention Program
    Ronald B Goldberg; Fiscal Year: 2010
    ....
  12. Mentored Career Development in Patient Oriented Research
    Daniel Rader; Fiscal Year: 2006
    ..abstract_text> ..
  13. Personal Digital Assistant for Guideline Adherence Trial
    David Goff; Fiscal Year: 2006
    ..Hence, this innovative strategy holds great promise for making a substantial public health impact through the prevention of CVD and through subsequent translation to other important conditions. ..
  14. Endothelial Dysfunction Due to HIV-1 Protease Inhibitors
    Mitchell Goldman; Fiscal Year: 2006
    ..abstract_text> ..
  15. Family Cardiac Caregiver Investigation to Evaluate Outcomes (FIT-O)
    Lori J Mosca; Fiscal Year: 2010
    ..Improved adherence to evidence-based preventive therapies could have a substantial public health benefit. ..
  16. Pharmacogenetics and Cardiovascular Events
    Bruce Psaty; Fiscal Year: 2006
    ..The primary defense is replication: we would therefore welcome collaboration from others in the Pharmacogenetics Network in validation efforts. ..
  17. Osteoblastogenesis in Aortic Valve Calcification
    Nalini Rajamannan; Fiscal Year: 2006
    ..If hypercholesterolemia stimulates the development of calcification in the aortic valve then the use of medical therapy such as HMG CoA reductase medications may have a role in the medical therapy of calcific aortic stenosis. ..
  18. REDUCTION OF TRIGLYCERIDES IN WOMEN ON HRT
    Lewis Kuller; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  19. MACROPHAGE EXPRESSION OF APOAI AND ATHEROSCLEROSIS
    Sergio Fazio; Fiscal Year: 2008
    ..These studies have the potential to uncover the basis for the therapeutic effect of HDL on the arterial plaque. [unreadable] [unreadable] [unreadable] [unreadable]..
  20. Validity of Diabetes Self-Reports in the Women's Health Initiative
    Karen Margolis; Fiscal Year: 2008
    ..The results of the study will help determine whether self-reported diabetes can be used for other analyses of the WHI data, and for post- menopausal women in other studies. [unreadable] [unreadable] [unreadable]..
  21. Diabetes and Drug-Associated Hyperkalemia: Effect of Laboratory Monitoring
    Marsha Raebel; Fiscal Year: 2008
    ..The findings will also assist in developing a framework for future studies to evaluate the effects and costs of medication-laboratory monitoring among patients with diabetes. [unreadable] [unreadable] [unreadable] [unreadable]..
  22. WGA Study to Identify Genetic Variants Associated with CV Events in CHS
    Bruce Psaty; Fiscal Year: 2009
    ..The proposed three-part study is efficient, has excellent power to detect small to modest-sized hazard ratios, provides a large sample of WG scans for aim 2, and includes an external replication. (End of Abstract) ..
  23. HDL metabolism: Influence of extracellular lipases
    Daniel Rader; Fiscal Year: 2009
    ....
  24. Vascular risk after kidney transplantation
    Jennifer L Larsen; Fiscal Year: 2010
    ..The study will also provide preliminary evidence for the efficacy of Vitamin D and omega 3 fatty acid supplementation in modifying traditional and nontraditional CVD risk factors as well as CVD progression after KTX. ..
  25. Genome-wide case-only study of antihypertensive drug-gene interactions
    Bruce M Psaty; Fiscal Year: 2010
    ....
  26. Hormone Replacement Therapy and Prothrombotic Variants
    Bruce Psaty; Fiscal Year: 2005
    ..Power for primary and secondary aims is excellent. Information from this project may help physicians counsel women about HRT to maximize either effectiveness, or safety, or both. ..
  27. ANTIHYPERTENSIVE DRUG/GENE INTERACTIONS AND CV EVENTS
    Bruce Psaty; Fiscal Year: 2004
    ..58 (the difference between an odds ratio of 0.46 and 0.79 in subjects with and without the variant, respectively). Power for other primary aims is excellent; power for secondary aims is good to excellent. ..
  28. Trends in and Outcomes of Medication Use in Older Adults
    Bruce Psaty; Fiscal Year: 2004
    ..abstract_text> ..
  29. NUTRITION ACADEMIC AWARD
    Michael Miller; Fiscal Year: 2004
    ..Compliance with ATP II and JNC VI recommendations will also be assessed. In addition, medical students' diets and blood lipid levels will be assessed and tracked. ..
  30. PROTEASE INHIBITOR-INDUCED HYPERLIPIDEMIA IN AIDS
    Virgil Brown; Fiscal Year: 2004
    ..These are specific agents that are effective in reducing triglyceride as well as improving insulin resistance. ..
  31. HIGH DENSITY LIPOPROTEIN SUBSPECIES AND CORONARY DISEASE
    Bela Asztalos; Fiscal Year: 2003
    ..The investigators state that these studies should provide better understanding about the diagnosis and treatment of HDL deficiency for the prevention of CHD. ..
  32. MUTATIONS, HORMONE THERAPY, AND VENOUS THROMBOEMBOLISM
    Bruce Psaty; Fiscal Year: 2001
    ....
  33. Gordon Research Conference: Lipoprotein Metabolism 2004
    Daniel Rader; Fiscal Year: 2004
    ....
  34. CELLULAR BASIS OF ANTIATHEROGENESIS BY APOLIPOPROTEIN E
    Daniel Rader; Fiscal Year: 2001
    ..These studies will provide greater understanding of the role of the local inflammatory response in atherosclerosis and its regulation by apoE. ..
  35. MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS
    Daniel Rader; Fiscal Year: 2004
    ..These studies will provide novel insights into the mechanisms of PI-associated dyslipidemia and atherosclerosis. ..
  36. MOLECULAR & CLINICAL EVALUATION OF LOW HDL SYNDROMES
    Michael Miller; Fiscal Year: 2003
    ..Further understanding of the molecular basis of isolated low HDL-C and its potential clinical sequelae (e.g., CAD), may therefore aid in the development of therapeutic strategies to effectively treat this disorder. ..
  37. Medication Use, Cormobidity and Outcomes in Aging Populations
    Robert J Glynn; Fiscal Year: 2010
    ..These studies are intended to advance methodologic strategies for evaluation of drug use and its effects in older people and to lay the foundation for interventions to improve prescribing in this population. ..
  38. Improving Hypertension Treatment in Africa
    Richard Cooper; Fiscal Year: 2003
    ..Whether our project yields a "positive" or "negative" result in relation to the main goal of identifying an effective clinical method, the outcome will have far-reaching implications for health care policy in that region. ..
  39. Consequences and Treatment of Growth Hormone Deficiency in the Metabolic Syndrome
    STEVEN KYLE GRINSPOON; Fiscal Year: 2010
    ..Lay Description: This grant will study how commonly low GH level are seen and contribute to increased cardiac risk in patients with abdominal fat and whether increasing low GH levels will improve cardiac risk in this population. ..
  40. GENE/DIET EFFECTS ON PLASMA LIPOPROTEIN LEVELS
    Jose M Ordovas; Fiscal Year: 2010
    ..This evidence-based knowledge will contribute to a rational approach toward more effective dietary recommendations aimed to decrease health disparities and to a better CVD prevention. ..
  41. Postprandial hyperglycemia and insulin secretion
    ANNETTE CHANG; Fiscal Year: 2003
    ..Oral glucose tolerance testing and 72-hour continuous glucose monitoring will be performed at baseline and at completion of the dosing period to assess the degree of normalization of postprandial hyperglycemia. ..
  42. Apo A2, C1 and C2 and Diet in human apoB Metabolism
    Frank Sacks; Fiscal Year: 2005
    ..abstract_text> ..
  43. CRP, Diabetes, Atherothrombosis
    Ishwarlal Jialal; Fiscal Year: 2010
    ..CRP augments oxidative stress and inflammation in the diabetic milieu will eventually lead to therapies targeted at reducing inflammation and oxidative stress in diabetes and resulting in a decrease in vasculopathies ..
  44. Multifactor Risk Reduction for Optimal Management in Peripheral Arterial Disease
    Roberta K Oka; Fiscal Year: 2010
    ..This study will examine the effect of a system that assists providers to reduce a patient's CVD risk factors and explores the biological reasons that this system may be effective in improving health. ..
  45. KINETICS OF HUMAN POSTPRANDIAL LIPOPROTEIN METABOLISM
    Frank Sacks; Fiscal Year: 2001
    ..These studies will increase our understanding of the metabolic pathways that are activated or suppressed postprandially, and could lead to treatments for reducing the development of atherosclerosis. ..
  46. A Case-crossover Study of Sharps-related injuries
    Murray Mittleman; Fiscal Year: 2005
    ..Successful completion of this study may identify modifiable risk factors for hospital-acquired sharps-related injuries. This knowledge may lead to individual and systems level risk-reduction interventions. ..
  47. MRFASS--MINORITIES, RISK FACTOR AND STROKE STUDY
    Stanley Tuhrim; Fiscal Year: 2003
    ..Stroke-free survival rates will be estimated for each ethnic group and the independent determinants of recurrence will be identified with multivariate statistical techniques. ..
  48. High Dose Alpha Tocopherol and Carotid Atherosclerosis
    Ishwarlal Jialal; Fiscal Year: 2004
    ..This study has the additional novelty of correlating biomarkers of oxidative stress and inflammation with a cardiovascular endpoint and will establish whether high dose AT decreases atherosclerosis progression. ..
  49. Individualized Expert Systems for Weight Management
    Sara Johnson; Fiscal Year: 2005
    ..Commercial applications include marketing to healthcare providers, namely managed care organizations, and employers who share the burden of healthcare expenses...
  50. MECHANISMS AND STRATEGIES FOR INSULIN RESISTANCE IN AIDS
    Steven Grinspoon; Fiscal Year: 2004
    ..The proposed studies represent a significant collaborative effort between clinical researchers, adipocyte biologists, epidemiologists and nutritional biochemists in satisfaction of the mandate of the RFA. ..
  51. VLDL and LDL Particle Types as CHD Risk Factors
    Frank Sacks; Fiscal Year: 2006
    ..abstract_text> ..
  52. Translating ATP III Cholesterol Management Guidelines *
    Charles Eaton; Fiscal Year: 2006
    ..abstract_text> ..
  53. Androgen Effects in HIV-Infected Women
    Steven Grinspoon; Fiscal Year: 2007
    ..The studies outlined in this renewal constitute an important investigative initiative of a targeted, gender-specific therapy in this largely understudied population. ..
  54. B VITAMIN ATHEROSCLEROSIS INTERVENTION TRAIL
    HOWARD HODIS; Fiscal Year: 2004
    ..B-vitamin supplementation may provide a promising approach for reducing the progression of atherosclerosis since it is natural, inexpensive, highly tolerable, and safe. ..
  55. Effects of a high glycemic load diet on vascular system
    John Rutledge; Fiscal Year: 2003
    ..We urgently need more information about the cardiovascular consequences of some of the commonly used diets in order to properly advise individuals and the public at-large about the long-term consequences of dieting. ..
  56. Impact of Medicaid Prescription Copayments in Patients with Schizophrenia
    Jalpa Doshi; Fiscal Year: 2009
    ..The findings of our study will help inform policymakers about the intended and unintended consequences of prescription copayments in Medicaid patients with schizophrenia. ..
  57. PREVENTION OF HEMODIALYSIS VASCULAR ACCESS STENOSIS
    Alfred K Cheung; Fiscal Year: 2010
    ..It is highly likely that, within this 5-year proposal, the results of this project can be applied to pilot clinical studies. ..
  58. ABCA1, ApoAI, and Lipid Efflux
    Jonathan Smith; Fiscal Year: 2008
    ..In addition, this study will include the identification of the apoAl oxidative modification by the enzyme myeloperoxidase that diminishes its lipid acceptor activity. ..
  59. Life Cycle Effects of Health Insurance on Elderly Health
    Jalpa Doshi; Fiscal Year: 2006
    ..We will use these estimates to simulate the effect of changes in the age of Medicare eligibility on health, medical service use and Medicare expenditure. ..
  60. Immune Thrombocytopenia and Low-Level Mercury Exposure
    Jodi Segal; Fiscal Year: 2006
    ..Segal with the necessary support for successful completion [unreadable] [unreadable] [unreadable]..